Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
002880.SZ
HOLDREMOVEShenzhen Weiguang Biological Products Co., Ltd. · Healthcare · China · $845M · Avg Vol: $5M/d
Shenzhen Weiguang Biological is a domestic Chinese blood products manufacturer. It operates in a highly regulated local market with no exposure to our core global macro themes or CDMO pricing power trends.
COMPANY DESCRIPTION
Shenzhen Weiguang Biological Products Co., Ltd. is a specialized biopharmaceutical company focused on the research, development, and manufacture of human blood products, including albumin, immunoglobulin, and coagulation factors. The company operates under a highly regulated licensing regime in China, which creates extremely high barriers to entry for new competitors. Its competitive moat is sustained by its network of proprietary plasma donation centers and strict quality control standards.
FINANCIAL SUMMARY
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 99M | 155M | 178M | 187M | 23.8% |
| EPS | 0.08 | 0.14 | 0.17 | 0.16 | 28.0% |
| Shares | 227M | 227M | 227M | 227M | 0.0% |
| Debt | 81M | 78M | 101M | 124M | 15.3% |
| Equity | 272M | 298M | 327M | 357M | 9.4% |
| Op CF | 177,211 | 59M | 26M | 39M | 503.2% |
| Inv CF | -72M | -52M | -35M | -38M | — |
| Fin CF | 66M | -13M | 12M | 13M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 002880.SZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 002880.SZ | Shenzhen Weiguang Biological Products Co., Ltd.(you) | $845M | 48 | HOLD |
| 688366.SS | Shanghai Haohai Biological Technology Co., Ltd. | $1.1B | 48 | HOLD |
| 688293.SS | Shanghai OPM Biosciences Co., Ltd. | $898M | 42 | HOLD |
| 600866.SS | Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | $1.2B | 46 | HOLD |
| 688767.SS | Hangzhou Biotest Biotech Co.,Ltd. | $842M | 39 | HOLD |
| 003020.SZ | Hefei Lifeon Pharmaceutical Co., Ltd. | $557M | 45 | HOLD |
| 603229.SS | Zhejiang Ausun Pharmaceutical Co., Ltd. | $1.2B | 43 | HOLD |
| 688202.SS | Shanghai Medicilon Inc. | $1.2B | 53 | HOLD |
| 688315.SS | Novogene Co., Ltd. | $870M | 60 | HOLD |
| 301333.SZ | R&G PharmaStudies Co., Ltd. | $724M | 38 | HOLD |
Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.1%